Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19171709 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Conditions: Diarrhea;   Drug/Agent Toxicity by Tissue/Organ;   Neuroblastoma
Interventions: Drug: cefixime;   Drug: irinotecan hydrochloride;   Drug: temozolomide

Indicates status has not been verified in more than two years